Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The company offers lanolin cholesterol series products, such as cholesterol and feed grade cholesterol; vitamin D3 products, including food additives compound nutrient fortifier SDS, food additives compound nutritional fortifier CO and MO, cholecalciferol, vitamin D3 particles, feed additive vitamin D3 oil, and VD3 resin oil; and 25 HydroxyVitamin D3 Progen, 25 hydroxyvitamin D3, and 25 hydroxyvitamin D3 powder. It also provides refined lanolin comprising anhydrous lanolin, wool oil, wool wax, low chroma ultra pure fat, lanolin alcohol, isopropyl lanolate, lanolinic acid, high acid fat, and wool acid biofuel/wool alcohol biofuel; and vitamin D3 environmental rodenticide. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
Research context
Zhejiang Garden Bio-chemical High-tech Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Zhejiang Garden Bio-chemical High-tech Co., Ltd is currently in a long term downtrend where the price is trading 9.2% below its 200 day moving average.
From a valuation standpoint, the stock is 3.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.0.
Zhejiang Garden Bio-chemical High-tech Co., Ltd's total revenue sank by 9.3% to $145M since the same quarter in the previous year.
Its net income has dropped by 19.5% to $64M since the same quarter in the previous year.
Finally, its free cash flow fell by 377.3% to $-91M since the same quarter in the previous year.
Based on the above factors, Zhejiang Garden Bio-chemical High-tech Co., Ltd gets an overall score of 0/5.